ONCY stock news · Oncolytics Biotech Inc.
Get alerts for ONCY
Follow Oncolytics Biotech Inc. (ONCY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ONCYONCOLYTICS BIOTECH INC: Other Events (ONCY)
NeutralOncolytics Biotech announced study data about pelareorep's effect on immune activity in HPV-driven tumors. The filing gives no findings or patient outcomes, so it does not change the company's outlook.
Oncolytics Biotech Inc. shares news about a trial and presentation at a big medical conference.
NeutralOncolytics Biotech announced plans to present a REO 033 study abstract and e-poster at ESMO 2026. No results are included, so the filing does not change the company's outlook.
Oncolytics Biotech Inc. says it will get a final payment for cancer research and share more study results.
NeutralOncolytics Biotech expects a final grant payment and more GOBLET study data. No payment amount or study findings are reported, so this filing does not change its outlook.
Oncolytics Biotech Inc. shares news about its patents and plans for pelareorep.
NeutralOncolytics Biotech said it is working to extend patent protection for pelareorep, but reported no result. The filing does not show a change in the company's outlook.
Oncolytics Biotech Inc. shares news about its colorectal cancer study.
NeutralOncolytics filed an update about its REO 033 colorectal cancer study. The excerpt gives no study findings, so it does not change the outlook for ONCY.
Oncolytics Biotech Inc. shares news about a study on pelareorep for treating colorectal cancer.
NeutralOncolytics announced preclinical study results but provided no data. The report does not change how we read the company today.